399 completed. 399 Phase 2, 86 Phase 1, 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 399 | Completed 399 |
| Phase 1 | 86 | Completed 86 |
| Phase 3 | 7 | Completed 7 |
Follow Brain Neoplasms: new trials by email Literature Review of Brain Neoplasms trials Research Report on Brain Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent RVP-001 - Central Nervous System (CNS) Lesions, Brain Metastases | Phase 2 | Completed | Reveal Pharmaceuticals Inc. | 18 | 2024-08-15 | 2025-12-26 |
| CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial Cognitive Behavioral Therapy for Insomnia - Primary Brain Tumor, Glioblastoma | Phase 2 | Completed | Virginia Commonwealth University | 70 | 2024-07-08 | 2025-10-01 |
| HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease Patritumab deruxtecan - Metastatic Breast Cancer, Advanced Non-Small Cell Squamous Lung Cancer | Phase 2 | Completed | MedSIR | 63 | 2023-11-24 | 2026-05-04 |
| Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases Serplulimab combined with bevacizumab and first-line chemotherapy - Non-small Cell Lung Cancer Stage II, Bevacizumab | Phase 2 / Phase 3 | Completed | Sun Yat-sen University | 40 | 2023-05-14 | 2024-11-13 |
| Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metastases Best Practice, Neuropsychological Assessment, Quality-of-Life Assessment - Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 110 | 2022-08-30 | 2026-10-21 |
| Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE) Furmonertinib 160 mg, Q.D. - Furmonertinib, EGFR-mutation | Phase 2 | Completed | Peking Union Medical College | 24 | 2022-07-11 | 2025-12-19 |
| Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation TY-9591 Tablets - NSCLC, EGFR Activating Mutation | Phase 2 | Completed | TYK Medicines, Inc | 29 | 2022-04-02 | 2024-12-30 |
| Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma TMZ, ipilimumab 3mg/kg, Nivolumab - Glioblastoma, Gliosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2021-12-08 | 2026-04-17 |
| Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System tozuleristide, Canvas imaging system, Surgical resection of tumor - Central Nervous System Tumor | Phase 2 | Completed | John Yu | 50 | 2021-09-30 | 2026-07-10 |
| Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma Dendritic cell vaccination + temozolomide-based chemoradiation, Dendritic cell vaccination +- conventional next-line treatment - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 1 / Phase 2 | Completed | University Hospital, Antwerp | 10 | 2021-09-10 | 2026-06-05 |
| MR-Linac Guided Adaptive FSRT for Brain Metastases From Non-small Cell Lung Cancer Unity-based MR-Linac guided FSRT - Non-small Cell Lung Cancer | Phase 2 | Completed | Sun Yat-sen University | 55 | 2021-06-01 | 2024-12-12 |
| Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients Pico G2 4K Headset with Applied VR software, Patient Reported Questionnaires, Saliva sample collection (hormones) - Anxiety | Phase 2 | Completed | National Cancer Institute (NCI) | 61 | 2021-03-18 | 2026-03-11 |
| Preoperative Stereotactic Radiosurgery for Brain Metastases Preoperative SRS - Brain Metastases | Phase 2 | Completed | Centre Jean Perrin | 70 | 2021-02-04 | 2026-11-20 |
| Comparison of Fluorescein-INtra-VItal Microscopy Versus Conventional Frozen Section Diagnosis for intraOperative Histopathological Evaluation Alcon - Intracranial Tumor | Phase 2 | Completed | Technical University of Munich | 210 | 2020-12-30 | 2022-11-10 |
| A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma Abemaciclib, Irinotecan, Temozolomide - Relapsed Solid Tumor, Refractory Solid Tumor | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 47 | 2020-11-09 | 2026-03-02 |
| LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma lerapolturev, pembrolizumab - Glioblastoma, Recurrent Glioblastoma | Phase 2 | Completed | Istari Oncology, Inc. | 25 | 2020-10-21 | 2025-06-05 |
| Keynatinib in Treated Patients With NSCLC and Brain Metastases Keynatinib - Non-Small Cell Lung Cancer With EGFR Mutation, Brain Metastases | Phase 2 | Completed | Medolution Ltd. | 16 | 2020-10-21 | 2025-01-22 |
| Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors 5-Aminolevulinic Acid Hydrochloride, Oral - Brain Tumor, Pediatric | Phase 2 | Completed | Universität Münster | 78 | 2020-09-25 | 2025-12-10 |
| Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC Tislelizumab, Carboplatin, Pemetrexed - NSCLC Stage IV, Brain Metastases | Phase 2 | Completed | Sun Yat-sen University | 36 | 2020-09-15 | 2023-05-25 |
| Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE) 18F fluciclovine - Brain Metastases | Phase 2 | Completed | Blue Earth Diagnostics | 23 | 2020-08-31 | 2025-07-20 |
Showing 20 of 399. Sign in to see all of them.
Glioblastoma (191) · Gliosarcoma (123) · Glioma (119) · Central Nervous System Neoplasms (109) · Astrocytoma (102) · Oligodendroglioma (80) · Breast Neoplasms (29) · Ependymoma (29) · Neoplasm Metastasis (28) · Carcinoma, Non-Small-Cell Lung (27) · Medulloblastoma (24) · Neoplasms (23) · Meningioma (22) · Melanoma (21)
Neoplasms by Site (397) · Brain Diseases (395) · Nervous System Neoplasms (395) · Central Nervous System Diseases (394) · Nervous System Diseases (394) · Neoplasms (376) · Central Nervous System Neoplasms (290) · Neoplasms by Histologic Type (290) · Neoplasms, Nerve Tissue (278) · Neuroectodermal Tumors (271) · Neoplasms, Germ Cell and Embryonal (270) · Neoplasms, Glandular and Epithelial (265) · Neoplasms, Neuroepithelial (253) · Glioma (132) · Astrocytoma (111)
Temozolomide (62) · Bevacizumab (49) · Radiotherapy (30) · Irinotecan (22) · Carboplatin (17) · Carmustine (11) · Cisplatin (11) · Cyclophosphamide (11) · Erlotinib Hydrochloride (11) · Etoposide (10) · Lapatinib (10) · Radiosurgery (10) · Filgrastim (9) · Sirolimus (8) · Sorafenib (8)
National Cancer Institute (NCI) (51) · Duke University (30) · M.D. Anderson Cancer Center (15) · Memorial Sloan Kettering Cancer Center (12) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (12) · New Approaches to Brain Tumor Therapy Consortium (9) · Novartis Pharmaceuticals (9) · Children's Oncology Group (7) · European Organisation for Research and Treatment of Cancer - EORTC (6) · Wake Forest University Health Sciences (6) · Radiation Therapy Oncology Group (5) · Alliance for Clinical Trials in Oncology (4) · Assistance Publique - Hôpitaux de Paris (4) · Case Comprehensive Cancer Center (4) · Jonsson Comprehensive Cancer Center (4)
United States (308) · Canada (43) · France (35) · Australia (21) · Spain (21) · Germany (20) · Italy (19) · Switzerland (19) · Netherlands (18) · China (16) · United Kingdom (15) · Belgium (14) · Austria (10) · Israel (8) · Puerto Rico (8)
Henry S. Friedman, MD (9) · David A. Reardon, MD (6) · Edward G. Shaw, MD (4) · Evanthia Galanis (4) · Lauren E. Abrey, MD (4) · Annick Desjardins, MD, FRCPC (3) · Betty Lawrence (3) · Darell D. Bigner, MD, PhD (3) · David Peereboom, MD (3) · Evanthia Galanis, MD (3) · Howard A. Fine, MD (3) · James J. Vredenburgh, MD (3) · Stanislaw R. Burzynski, MD, PhD (3)
PMID 25098701, PMID 11772431, PMID 11907388, PMID 1408229, PMID 14586216, PMID 14625709, PMID 14670747, PMID 14769136, PMID 14769138, PMID 14769140, PMID 15073861, PMID 15292713, PMID 15514370, PMID 15758009, PMID 16012795, PMID 16034522, PMID 16133802, PMID 16170172, PMID 16314647, PMID 16533878, PMID 16549835, PMID 16817692, PMID 16863926, PMID 16877733, PMID 16890064, PMID 16914578, PMID 17031561, PMID 17317837, PMID 17418968, PMID 17470857, PMID 17610262, PMID 17987262, PMID 18094423, PMID 18182667, PMID 18215105, PMID 18623206, PMID 18661102, PMID 18824712, PMID 18850068, PMID 18981004, PMID 18981465, PMID 18989154, PMID 19066728, PMID 19188181, PMID 19204207, PMID 19262392, PMID 19562254, PMID 19720927, PMID 19920819, PMID 20143438
U01CA062399 (8), 2014 (6), U10CA025224 (6), U10CA021661 (5), U01CA062475 (4), U01CA137443 (4), 2017 (3), P30CA008748 (3), U10CA098543 (3), U10CA180868 (3), 2009 (2), 2015 (2), 2019 (2), 2023 (2), P30CA015704 (2)